Eledon Pharmaceuticals, Inc. (ELDN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing tegoprubart, an anti-CD40L antibody, for the prevention of organ transplant rejection (kidney and islet cell) and the treatment of amyotrophic lateral sclerosis (ALS). The company operates as a single segment and has no approved products for commercial sale.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(11.2) million | $(17.7) million | $(68.5) million |
| Operating Expenses | $24.7 million | $42.7 million | $25.4 million |
| Cash & Short-Term Investments | $107.6 million (as of June 30, 2025) | ||
| Working Capital | $97.7 million (as of June 30, 2025) | ||
| Accumulated Deficit | $(373.3) million (as of June 30, 2025) | ||
| Warrant Liabilities | $22.5 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the six months ended June 30, 2025, decreased significantly to $17.7 million compared to $68.5 million in the same period in 2024. This improvement was primarily driven by a $22.4 million gain from the change in fair value of warrant liabilities (a non-cash item), whereas the prior year included a $44.6 million loss in this category.
- Increased Operating Expenses: Total operating expenses rose by $17.3 million year-over-year to $42.7 million. Research and Development (R&D) expenses increased by $16.3 million, driven by higher costs for the Phase 2 BESTOW kidney transplant trial, manufacturing of clinical supplies, and increased personnel headcount.
- Cash Position: Cash and cash equivalents decreased from $20.5 million at year-end 2024 to $5.7 million at June 30, 2025, though total liquid assets (including short-term investments) remain at $107.6 million.
Guidance, Outlook, and Risks
- Clinical Milestones: The company completed enrollment in the Phase 2 BESTOW kidney transplant study in September 2024 and expects to present topline results in November 2025. Positive interim data was reported in October 2024 for an investigator-initiated islet cell transplant study, showing insulin independence in early subjects.
- Liquidity Outlook: Management estimates current resources are sufficient to fund operations for at least the next 12 months. However, the company explicitly states it lacks sufficient liquidity to continue the clinical development of tegoprubart for ALS without additional financing.
- Restatement of Financials: The company restated prior period financial statements to reclassify Series X and Series X1 preferred stock from permanent equity to temporary equity and to apply the two-class method for earnings per share calculations.
- Material Weakness: The company disclosed a material weakness in internal controls over financial reporting, which contributed to the restatements. Remediation efforts are ongoing.
- Risk Factors: Key risks include the need for additional capital to fund operations and specific programs (ALS), the uncertainty of clinical trial outcomes, and potential dilution from future equity issuances.
Investor Verification Checklist
- Verify the timeline and expected data readout for the Phase 2 BESTOW kidney transplant trial (anticipated November 2025).
- Confirm the specific funding requirements and potential financing strategies for the ALS program, which is currently unfunded.
- Review the status of the remediation plan for the material weakness in internal controls over financial reporting.
- Monitor the fair value of warrant liabilities, as fluctuations in stock price significantly impact reported net loss.
- Assess the impact of the preferred stock reclassification on the capital structure and potential dilution upon conversion.